Developing a new therapeutic takes time, especially when it’s being held back by legacy data management systems. Using the traditional pen-and-paper approach to capture and store data is unreliable – it ensures that data is siloed, and most likely then forgotten.
We know that without access to data and the ability to share it with colleagues, drawing insight is impossible. The knock-on effect here is that innovation is stagnant and throughput reduced.
Research shows that 90 percent of businesses now use cloud technology to increase productivity. Teams use Slack to communicate, marketing and sales use Salesforce, and creatives use Adobe. Similarly, implementing cloud software in the life sciences sector can increase productivity – speeding up research and development (R&D) by 20 percent. This presents a solid business case for technology that scales along with needs and supports all aspects R&D in one single and integrated platform.
For organisations looking to upgrade their data management system, there are a variety of reasons moving to the cloud is a good idea. It is more scalable and cheaper than on-premise as well as being faster to deploy and easier to use. Cloud software requires minimal training – if you use the internet, then you are already familiar with it.
In R&D, where time and costs are major decision drivers, it’s a gamechanger – there is great potential to significantly increase the throughput of viable drugs and therapeutics.
Strengthen collaborations and share data instantly 
When collaborating with an internal or external team, it’s important to be clear on what needs to be done, who’s doing it, and when. But if your data capture tools are outdated and ineffective, data might be incomplete, inaccurate, or missing altogether. Communicating with partners and gaining insight from that data becomes challenging at best.
There is room for these issues and many more to develop when

View Entire Article on